2022 American Transplant Congress
Utility of Cytomegalovirus T-Cell Immunity Panel to Predict CMV Infections in Lung Transplant Recipients
*Purpose: Given the limited data of cytomegalovirus T-cell immunity panels (CMV TCIP) in lung transplant recipients (LTR), we sought to describe our center’s experience with…2022 American Transplant Congress
Oseltamivir for the Prevention of Influenza Infection in Lung Transplant Recipients at an Academic Medical Center
Temple University Hospital, Philadelphia, PA
*Purpose: Influenza is commonly considered a community acquired infection, but in transplant recipients, nosocomial transmission is frequently encountered. The lung transplant program at Temple University…2022 American Transplant Congress
Evaluation of Voriconazole Dosing for Preventing Aspergillus in Lung Transplant Recipients
*Purpose: We sought to evaluate the efficacy of voriconazole (VCZ) 200 mg twice a day (BID) for 3 months post lung transplant (LT) in preventing…2022 American Transplant Congress
Impact of Mycetoma in Lung Transplant Recipients
*Purpose: Mycetoma are uncommon in lung transplant recipients (LTRs) and previous studies describe poor outcomes. We reviewed our experience*Methods: Retrospective review of electronic medical records…2022 American Transplant Congress
Impact of Respiratory Viral Panel Testing on Clinical Decision-Making Among Lung Transplant Recipients Based on Extent of Immunosuppression
*Purpose: Lung transplant recipients (LTRs) are at high risk for complications from viral respiratory infection, including chronic allograft dysfunction. Thus, multiplex molecular testing for respiratory…2022 American Transplant Congress
Effect of Micafungin Bridging on Prevention of Invasive Candidiasis Post Lung Transplantation
*Purpose: This study aims to determine the effect of micafungin, added as a bridging agent to azole antifungal prophylaxis, in lung transplantation patients with positive…2022 American Transplant Congress
Risk Factors Associated with ICU Admission and Death in Patients Hospitalized with COVID-19 Differ Between Solid Organ Transplant and Non-Solid Organ Transplant Patients
David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Despite the large numbers of reports on patient risk factors for poor clinical outcomes with COVID-19, little is known about how these risks may…2022 American Transplant Congress
Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study
*Purpose: Immunocompromised hosts are at risk for severe complications or death from SARS-CoV-2 infection. Few studies describe the clinical features, outcomes and treatment strategies in…2022 American Transplant Congress
Early Clinical Experience With Alvr109, A Partially Hla-matched Sars-cov-2 Specific T-cell Therapy, In Immunocompromised Patients With Covid-19
1University of Pittsburgh, Pittsburgh, PA, 2UPitt, Pittsburgh, PA, 3Allovir, Waltham, MA
*Purpose: Therapies for COVID-19 in immunocompromised (IC) patients (pts), including transplant (tx) pts, are limited. We describe our experience with ALVR109, an allogeneic, partially HLA-matched…2022 American Transplant Congress
Inhalation Alone versus Inhalation Plus Intravenous Colistin for Multidrug-Resistant Gram-Negative Bacterial Infection After Lung Transplantation
*Purpose: After lung transplantation, patients are exposed to the risk of various infections accounting for morbidity and mortality. Multidrug-resistant gram-negative (MDR-GN) bacteria are emerging pathogen.…
- 1
- 2
- 3
- 4
- Next Page »